Nebivolol efficacy and safety in patients with stage I-II hypertension

Clinical Cardiology

Volumn 33, Issue 4, 2010, Pages

  Greathouse, Mark ^a  

^a South Hill Cardiology Associates   (United States)

Author keywords

Blockers; Hypertension; Nebivolol; Nitric oxide; Tolerability

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; PLACEBO;

ADULT; ANEURYSM RUPTURE; AORTA ANEURYSM; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 77950814414     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20508     Document Type: Article

References (17)

1. Prichard BN, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001;10(5-6):366-386.
2. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(12 pt 2): 169S-176S.
3. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236.
4. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92(3):344-348.
5. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998;38(6):419-431.
6. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57(4):633-651.
7. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667-676.
8. Saunders E, SmithWB,DeSalvo KB, SullivanWA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866-875.
9. Gradman A. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker associated adverse events with placebo. J Clin Hypertens (Greenwich). 2008;10(5 suppl A): A120-Y.
10. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B,Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35-40.
11. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens. 2006;8(suppl 4):40-52.
12. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005;18(12 Pt 2):177S-183S.
13. Dawes M, Brett SE, Chowienczyk PJ, Mant TGK, Ritter JM. The vasodilatory action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463.
14. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/ NO-dependent mechanism. J Pharmacol Exper Therapeut. 1995; 274:1067-1071.
15. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double-blind crossover study. Circulation. 2001; 104:511-514.
16. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11(12):813-819. (Pubitemid 28043340)
17. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12(2):135-140.